

MAXIMUM URETHRAL CLOSURE PRESSURE AS A PREDICTOR OF SUCCESS WITH SACRAL NEUROMODULATION (ABSTRACT 330) Bueno P<sup>1</sup>, Thomas L<sup>2</sup>, Hashim H<sup>2</sup>



<sup>1</sup>National Institute of Medical Science and Nutrition,<sup>2</sup> Bristol Urological Institute

BACKGROUND		RESULTS
Sacral neuromodulation (SNM established treatment for refra overactive bladder (OAB) synd voiding dysfunction (VD). All patients are subjected to a determines if the patient is like from a permanent SNM implar There are no known predictors for this therapy.	ctory frome and test phase that ly to benefit it.	Assessed for eligibility (n= 65) Excluded (n= 52) -Did not meet inclusion criteria 1st stage SNM (n= 13) 250% improvement in symptoms Unsuccessful (n= 2) • Patient 1: MUCP 63cmH <sub>2</sub> O (dx VD) • Patient 2: MUCP 83cmH <sub>2</sub> O (dx VD+OAB)
AIM OF STUDY Determine if a high maximum urethral closure pressure (MUCP) correlates with sacral neuromodulation success in female patients with voiding dysfunction. METHODS		A maximum urethral closure pressure value of 101 was calculated with ROC curve with the best AUC of 0.86. On univariate analysis, MUCP $\geq$ 90 cmH2O was associated with SNM success, with an OR of 5.5 ( <i>p</i> = 0.027). A MUCP of 90 cmH2O or above, confers 5.5 more chance of having a successful clinical response with SNM in VD.
Retrospective observational study of prospectively collected data from 65 patients who underwent static urethral pressure profilometry (UPP) as part of urodynamic investigations before sacral neuromodulation placement (2012-2017). We selected female patients with VD in UDS and postvoid residual urine (PVR) more than 100mL, who where candidates for SNM. Sacral neuromodulation test phase success was defined by 50% improvement in symptoms at the outpatient clinic. We used an MUCP cut-off of 90 cmH2O, based on clinical judgment. Logistic regression analysis was performed to identify perioperative factors associated with sacral neuromodulation success.		SUCCESSFUL SNM
Demographics and characteristics		CONCLUSIONS
Age (years)	27.3 (± 10.5)	MUCP appears to be a useful tool for
Diagnosis (no. patients) VD VD + OAB VD + pelvic pain	8 4 1	predicting success of sacral neuromodulation therapy in women with voiding dysfunction. Further studies with larger populations are warranted to confirm this observation.
REFERENCES		
<ol> <li>DasGUPTA, R. A. N. A. N., &amp; Fowler, C. J. (2004). Urodynamic study of women in urinary retention treated with sacral neuromodulation. <i>The Journal of urology</i>, 171(3).</li> <li>Elneil, S. (2010). Urinary retention in women and sacral neuromodulation. <i>International urogynecology journal</i>, 21(2).</li> </ol>		

2.Elneil, S. (2010). Urinary retention in women and sacral neuromodulation. *International urogynecology journal*, 21(2). 3.Goh, M., & Diokno, A. C. (2007). Sacral neuromodulation for nonobstructive urinary retention—is success predictable?. *The Journal of urology*, 178(1).

4. De Ridder, D., Ost, D., & Bruyninckx, F. (2007). The presence of Fowler's syndrome predicts successful long-term outcome of sacral nerve stimulation in women with urinary retention. *european urology*, *51*(1).

5. Wiseman, O. J., Swinn, M. J., Brady, C. M., & Fowler, C. J. (2002). Maximum urethral closure pressure and sphincter volume in women with urinary retention. *The Journal of urology*, *167*(3).